Wesley Armstrong

MD PhD Student, UCLA-Caltech MSTP

[Amar Kishan @AmarUKishan]

Great work out in @EUplatinum led by @Wes_Armstrong_ on our @UCLAJCCC SRT randomized trial of PSMA vs SOC imaging before SRT, led by @CalaisJeremie and Nick Nickols

[PSMA & Beyond Conference @PSMAconference]

Great poster presentations and reception at the #2024PSMAConference! Congratulations to our awardees - Reinier Hernandez, @josef_zahner, and @Wes_Armstrong_ !

[. @UCLAJCCC]

New study led by UCLA & UCSF finds PSMA PET, a molecular imaging tool, can provide prognostic information before treatment begins that can predict if the patient will have a high risk for prostate cancer returning after surgery.

https://t.co/E5iKCPlDY7

[Jeremie Calais @CalaisJeremie]

Follow-up of the surgical cohort of the Pivotal Trial used for the FDA approval of 68Ga-PSMA-11 PET in @EUplatinum: Pre-surgical PSMA-PET is a strong prognostic biomarker improving pre-operative BCR-FS risk assessment.
https://t.co/c2Zw9n97Zm
https://t.co/HjyxxGY5Qt

[Jeremie Calais @CalaisJeremie]

The #UCLA Nuclear Medicine Clinical Research Team presented 7 abstracts on PSMA-PET/CT at #ASCO23. Little by little, we try to learn and share how to interpret and use the PSMA-PET information for Optimizing Treatment Decision-Making.
https://t.co/ItLoF1hXij

[UroToday.com @urotoday]

PSMA PET guided salvage radiotherapy among patients with #ProstateCancer in the post-prostatectomy setting: a single center posthoc analysis. Presented by @CalaisJeremie @UCLAJCCC. #ASCO23 written coverage by @RKSayyid @UofT > https://t.co/7YO0wE840o @ASCO

[UroToday.com @urotoday]

Pre-surgical 68Ga-PSMA-11 PET for biochemical recurrence risk assessment: a surrogate of pelvic lymph node dissection? Follow-up analysis of a multicenter prospective phase 3 imaging trial. Presented by @DjailebLoic @UCLATheranostic > https://t.co/lAro7c1iWX @zklaassen_md #ASCO23

[Jeremie Calais @CalaisJeremie]

@claysmithmd Great work @claysmithmd

[UroToday.com @urotoday]

PSMA PET findings in an “EMBARK-like” cohort of pts with high-risk #nmHSPC: a single center posthoc retrospective analysis. Presented by Wesley Armstrong @uclacaltechmstp. #ASCO23 written coverage by @zklaassen_md @GACancerCenter > https://t.co/39xOmo58zi @ASCO

[Zach Klaassen @zklaassen_md]

PSMA PET findings in an “EMBARK-like” cohort of HR nmHSPC @Wes_Armstrong_ @CalaisJeremie

📌 n=183
📌 med PSA: 2.4 (RP), 6.9 (dRT), 2.7 (RP+SRT), 2.8 (overall pop)
📌 PSMA PET+: 85.2%; 609 PSMA PET+ lesions; 3.9 mean number of lesions/case. 46% M1 dx!

@urotoday #ASCO23

[Amar Kishan @AmarUKishan]

Great trial led by Nick Nickols and @CalaisJeremie @UCLAJCCC